Short answer
Lucid Diagnostics Inc. (LUCD) filed an 8-K current report with the SEC on September 22, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Boilerplate Regulation FD disclaimer only; no substantive investor disclosure in the provided text.
Lucid Diagnostics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Boilerplate Regulation FD disclaimer only; no substantive investor disclosure in the provided text
Item EX-99.1 · Exhibit EX-99.1
- CMS advisory panel recommended preserving EsoGuard’s original gapfill payment basis under CLFS for PLA code 0114U
- Final Medicare payment determination expected in November after public comment, reducing near-term reimbursement uncertainty
- New Category III CPT code approved for EsoCheck nonendoscopic cell collection, enabling physician reporting and utilization tracking
- Proposed ICD-10-CM code R85.83 positively received, supporting documentation for follow-up endoscopy after positive EsoGuard results
- Texas laboratory begins Medicare claims under code 0114U this month; California claims await revised LCD after reconsideration
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Lucid Diagnostics Inc. 8-K filings
Get the next LUCD 8-K as it lands
Follow LUCD for push alerts, or ask the research agent what this filing means.